Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 10/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820371 | 0.90 | TSHR (0.48) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL7490029 | 0.89 | GLA (0.40) | TSHRGLANPSR1LMNAEGLN2 | |
| SCHEMBL7491155 | 0.89 | TSHR (0.41) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL7491260 | 0.88 | TSHR (0.37) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL4820964 | 0.87 | PDE2A (0.42) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL344327 | 0.87 | TSHR (0.46) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL7488186 | 0.86 | TSHR (0.38) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL4816609 | 0.86 | ALDH1A1 (0.37) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL7490417 | 0.86 | ALDH1A1 (0.37) | TSHRGLANPSR1ALDH1A1LMNA | |
| SCHEMBL7488259 | 0.86 | ALDH1A1 (0.37) | TSHRGLANPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0945453-B1 | Fungicidal trifluorophenyl-triazolopyrimidines | BASF AG (DE) | 2002-11-20 | — | — | EP | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| EP-0945453-A1 | Fungicidal trifluorophenyl-triazolopyrimidines | American Cyanamid Company (US) | 1999-09-29 | — | — | EP | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| EP-0945453-B1 | Fungicidal trifluorophenyl-triazolopyrimidines | BASF AG (DE) | 2002-11-20 | — | — | EP | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6117865-A | FOR CONTROLLING FUNGUS IN PLANTS | AMERICAN CYANAMID COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0945453-A1 | Fungicidal trifluorophenyl-triazolopyrimidines | American Cyanamid Company (US) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | TSHR 2567/4885GLA 3009/4885NPSR1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.